Patents by Inventor Julja Burchard
Julja Burchard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230408530Abstract: The present invention provides compositions and methods for due date and time to birth prediction for a pregnancy with significantly higher accuracy than current clinical methods. The compositions and methods for due date and time to birth prediction for a pregnancy can also identify those pregnancies that will deliver earlier than the due date derived from LMP and/or US dating.Type: ApplicationFiled: March 31, 2023Publication date: December 21, 2023Inventors: John Jay Boniface, Paul Edward Kearney, Julja Burchard, Gregory Charles Critchfield, Durlin Edward Hickok, Tracey Cristine Fleischer, Ashoka Dharmapriya Polpitiya
-
Patent number: 11662351Abstract: Compositions and methods for predicting due date and time to birth for a pregnancy with significantly higher accuracy than current clinical methods. The compositions and methods for predicting due date and time to birth for a pregnancy can also identify those pregnancies that will deliver earlier than the due date derived from Last Menstrual Period (LMP) and/or obstetric ultrasonography (US) dating.Type: GrantFiled: August 17, 2018Date of Patent: May 30, 2023Assignee: Sera Prognostics, Inc.Inventors: John Jay Boniface, Paul Edward Kearney, Julja Burchard, Gregory Charles Critchfield, Durlin Edward Hickok, Tracey Cristine Fleischer, Ashoka Dharmapriya Polpitiya
-
Publication number: 20220025462Abstract: The present invention provides compositions and methods for determining a pregnant female's risk of developing placental dysfunction later in the pregnancy.Type: ApplicationFiled: December 9, 2019Publication date: January 27, 2022Inventors: John Jay Boniface, Julja Burchard, Ryan Michael Treacy, Louise C. Laurent
-
Publication number: 20210190792Abstract: The present invention provides compositions and methods for predicting the probability of preterm birth in a pregnant female. The present invention provides a composition comprising one or more biomarkers selected from the group consisting of the biomarkers set forth in FIGS. 1 and 2 and Tables 1 through 3, 6 through 38, and 44 through 68. In one embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, optionally preterm birth associated with preterm premature rupture of membranes (PPROM) or preterm birth associated idiopathic spontaneous labor (PTL), the method comprising measuring in a biological sample obtained from the pregnant female one or biomarkers selected from one or more of the biomarkers set forth in FIGS. 1 and 2 and Tables 1 through 3, 6 through 38, and 44 through 68 to determine the probability for preterm birth in said pregnant female.Type: ApplicationFiled: August 5, 2020Publication date: June 24, 2021Inventors: John Jay Boniface, Julja Burchard, Gregory Charles Critchfield, Tracey Cristine Fleischer, Durlin Edward Hickok, Chien Hsu
-
Publication number: 20190369109Abstract: The present invention provides compositions and methods for predicting the probability of preterm birth in a pregnant female. The present invention provides a composition comprising one or more biomarkers selected from the biomarkers set forth in FIGS. 1, 3 through 12 and Tables 7 through 19, or optionally at least one pair of biomarkers selected from the biomarkers listed Tables 7 through 19, wherein the pair consists of one overexpressed and one underexpressed biomarker of the biomarkers set forth in Tables 7 through 19. In one embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, optionally in a pregnant female treated with a progestogen (e.g., 17-alpha hydroxyprogesterone caproate (17P)), the method comprising measuring in a biological sample obtained from the pregnant female one or biomarkers selected from the group consisting of one or more of the biomarkers of the invention.Type: ApplicationFiled: December 21, 2018Publication date: December 5, 2019Inventors: John Jay Boniface, Julja Burchard, Gregory Charles Critchfield, Tracey Cristine Fleischer, Durlin Edward Hickok, Todd Lenwell Randolph, Babak Shahbaba
-
Publication number: 20190234954Abstract: The present invention provides compositions and methods for due date and time to birth prediction for a pregnancy with significantly higher accuracy than current clinical methods. The compositions and methods for due date and time to birth prediction for a pregnancy can also identify those pregnancies that will deliver earlier than the due date derived from LMP and/or US dating.Type: ApplicationFiled: August 17, 2018Publication date: August 1, 2019Inventors: John Jay Boniface, Paul Edward Kearney, Julja Burchard, Gregory Charles Critchfield, Durlin Edward Hickok, Tracey Cristine Fleischer, Ashoka Dharmapriya Polpitiya
-
Publication number: 20180172698Abstract: The present invention provides compositions and methods for predicting the probability of preterm birth in a pregnant female. The present invention provides a composition comprising one or more biomarkers selected from the group consisting of the biomarkers set forth in FIGS. 1 and 2 and Tables 1 through 3, 6 through 38, and 44 through 68. In one embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, optionally preterm birth associated with preterm premature rupture of membranes (PPROM) or preterm birth associated idiopathic spontaneous labor (PTL), the method comprising measuring in a biological sample obtained from the pregnant female one or biomarkers selected from one or more of the biomarkers set forth in FIGS. 1 and 2 and Tables 1 through 3, 6 through 38, and 44 through 68 to determine the probability for preterm birth in said pregnant female.Type: ApplicationFiled: August 4, 2017Publication date: June 21, 2018Inventors: John Jay BONIFACE, Julja Burchard, Gregory Charles Critchfield, Tracey Cristine Fleischer, Durlin Edward Hickok, Chien Hsu
-
Publication number: 20180143202Abstract: The present invention provides compositions and methods for predicting the probability of preterm birth in a pregnant female. The present invention provides a composition comprising one or more biomarkers selected from the biomarkers set forth in FIGS. 1, 3 through 12 and Tables 7 through 19, or optionally at least one pair of biomarkers selected from the biomarkers listed Tables 7 through 19, wherein the pair consists of one overexpressed and one underexpressed biomarker of the biomarkers set forth in Tables 7 through 19. In one embodiment, the invention provides a method of determining probability for preterm birth in a pregnant female, optionally in a pregnant female treated with a progestogen (e.g., 17-alpha hydroxyprogesterone caproate (17P)), the method comprising measuring in a biological sample obtained from the pregnant female one or biomarkers selected from the group consisting of one or more of the biomarkers of the invention.Type: ApplicationFiled: August 4, 2017Publication date: May 24, 2018Inventors: John Jay BONIFACE, Julja Burchard, Gregory Charles Critchfield, Tracey Cristine Fleischer, Durlin Edward Hickok, Todd Lenwell Randolph, Babak Shahbaba
-
Patent number: 9200275Abstract: In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one at least one small interfering RNA agent (iRNA), wherein said iRNA comprises a nucleotide sequence of at least 15 nucleotides, wherein the nucleotide sequence comprises a seed region consisting of nucleotide positions 1 to 12, wherein position 1 represents the 5? end of the iRNA nucleotide sequence and wherein said seed region comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to six contiguous nucleotides within positions 1 to 12 of a nucleotide sequence, wherein position 1 represents the 5?end of the nucleotide sequence, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.Type: GrantFiled: June 14, 2007Date of Patent: December 1, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Peter S. Linsley, Janell Schelter, Julja Burchard, Lee Lim, Miho Kibukawa
-
Publication number: 20140088937Abstract: The present invention provides a method for determining the probability that an RNAi compound modulates the expression level of a gene using a linear regression model. The present invention also provides a method for determining the probabilities that an RNAi compound modulates the expression levels of each gene in a set of genes of interest using the linear regression model. The present invention provides a method for determining the seed-sequence-dependent signature size of an RNAi compound using the linear regression model. The invention provides a method for identifying genes having seed-sequence-dependent silencing effect by an siRNA using the linear regression model. The invention further provides a method for selecting from a plurality of siRNAs one or more siRNAs with higher silencing efficacy, specificity and diversity in silencing a target gene in an organism. The invention also provides a method for determining the coefficients of the above linear regression model.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: Merk Sharp & Dohme Corp.Inventors: Duncan Brown, Julja Burchard, Eugen C. Buehler
-
Patent number: 8609830Abstract: The invention provides methods and compositions for gene silencing by RNA interference. In particular, the invention provides methods for gene silencing or RNA knockdown using small interfering RNAs (siRNAs) having partial sequence homology to its target gene. The invention also provides methods for identifying common and/or differential responses to a plurality of different siRNAs targeting a gene. The invention also provides methods for evaluating the relative activity of the two strands of an siRNA. The invention further provides methods of designing siRNAs for gene silencing. The invention further provides methods of using siRNAs as therapeutics for treatment of diseases.Type: GrantFiled: May 17, 2004Date of Patent: December 17, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Aimee L. Jackson, Steven R. Bartz, Julja Burchard, Janell M. Schelter, Peter S. Linsley
-
Patent number: 8457902Abstract: The present invention provides a method for identifying siRNA target motifs in a transcript using a position-specific score matrix approach. The invention also provides a method for identifying off-target genes of an siRNA using a position-specific score matrix approach. The invention further provides a method for designing siRNAs with higher silencing efficacy and specificity. The invention also provides a library of siRNAs comprising siRNAs with high silencing efficacy and specificity.Type: GrantFiled: May 4, 2011Date of Patent: June 4, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Aimee L. Jackson, Steven R. Bartz, Julja Burchard, Peter S. Linsley, Ge Wei, Guy L. Cavet
-
Patent number: 8399248Abstract: In one aspect, the invention generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell. In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.Type: GrantFiled: May 5, 2008Date of Patent: March 19, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Michele A. Cleary, Aimee L. Jackson, Peter S. Linsley, Julja Burchard, Lee P. Lim, Jill F. Magnus, Lin He, Xingyue He, Scott W. Lowe, Gregory J. Hannon
-
Patent number: 8378088Abstract: In one aspect, the invention generally relates to compositions comprising miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.Type: GrantFiled: May 5, 2008Date of Patent: February 19, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Michele A Cleary, Aimee L Jackson, Peter S Linsley, Julja Burchard, Lee P Lim, Jill F Magnus
-
Publication number: 20120072123Abstract: The present invention provides a method for determining the probability that an RNAi compound modulates the expression level of a gene using a linear regression model. The present invention also provides a method for determining the probabilities that an RNAi compound modulates the expression levels of each gene in a set of genes of interest using the linear regression model. The present invention provides a method for determining the seed-sequence-dependent signature size of an RNAi compound using the linear regression model. The invention provides a method for identifying genes having seed-sequence-dependent silencing effect by an siRNA using the linear regression model. The invention further provides a method for selecting from a plurality of siRNAs one or more siRNAs with higher silencing efficacy, specificity and diversity in silencing a target gene in an organism. The invention also provides a method for determining the coefficients of the above linear regression model.Type: ApplicationFiled: May 27, 2010Publication date: March 22, 2012Applicant: Merck & Co., Inc.Inventors: Duncan Brown, Julja Burchard, Eugen C. Buehler
-
Publication number: 20110250591Abstract: The present invention provides a method for identifying siRNA target motifs in a transcript using a position-specific score matrix approach. The invention also provides a method for identifying off-target genes of an siRNA using a position-specific score matrix approach. The invention further provides a method for designing siRNAs with higher silencing efficacy and specificity. The invention also provides a library of siRNAs comprising siRNAs with high silencing efficacy and specificity.Type: ApplicationFiled: May 4, 2011Publication date: October 13, 2011Applicant: MERCK SHARP & DOHME CORP.Inventors: Aimee L. Jackson, Steven R. Bartz, Julja Burchard, Peter S. Linsley, Wei Ge, Guy L. Cavet
-
Patent number: 7962316Abstract: The present invention provides a method for identifying siRNA target motifs in a transcript using a position-specific score matrix approach. The invention also provides a method for identifying off-target genes of an siRNA using a position-specific score matrix approach. The invention further provides a method for designing siRNAs with higher silencing efficacy and specificity. The invention also provides a library of siRNAs comprising siRNAs with high silencing efficacy and specificity.Type: GrantFiled: October 27, 2004Date of Patent: June 14, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Aimee L. Jackson, Steven R. Bartz, Julja Burchard, Peter S. Linsley, Wei Ge, Guy L. Cavet
-
Publication number: 20110105583Abstract: In one aspect, the invention generally relates to use of miR-34 as a biomarker to estimate TP53 function in a cell. In another aspect, the invention generally relates to multiple uses of miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.Type: ApplicationFiled: May 5, 2008Publication date: May 5, 2011Applicants: MERCK & CO., INC., COLD SPRING HARBOR LABORATORYInventors: Michele A. Cleary, Aimee L. Jackson, Peter S. Linsley, Julja Burchard, Lee P. Lim, Jill F. Magnus, Lin He, Xingyue He, Scott W. Lowe, Gregory J. Hannon
-
Publication number: 20100227909Abstract: In one aspect, the invention generally relates to compositions comprising miR-34 and siRNAs functionally and structurally related to miR-34 for the treatment of cancer.Type: ApplicationFiled: May 5, 2008Publication date: September 9, 2010Applicant: Merck Sharp & Dohme Corp.Inventors: Michele A. Cleary, Aimee L. Jackson, Peter S. Linsley, Julja Burchard, Lee P. Lim, Jill F. Magnus
-
Publication number: 20100035966Abstract: In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one at least one small interfering RNA agent (iRNA), wherein said iRNA comprises a nucleotide sequence of at least 15 nucleotides, wherein the nucleotide sequence comprises a seed region consisting of nucleotide positions 1 to 12, wherein position 1 represents the 5? end of the iRNA nucleotide sequence and wherein said seed region comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to six contiguous nucleotides within positions 1 to 12 of a nucleotide sequence, wherein position 1 represents the 5?end of the nucleotide sequence, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.Type: ApplicationFiled: June 14, 2007Publication date: February 11, 2010Applicant: ROSETTA INPHARMATICS LLCInventors: Peter S. Linsley, Janell Schelter, Julja Burchard, Lee Lim, Miho Kibukawa